Targovax ASA (Targovax or the Company; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovax’s CFO, will become Chief Business Officer, replacing Michael Bogenstaetter
Johanna Ivaska, Academy Professor of Biochemistry has been appointed Head & Vice President of Oncology Research in Orion Corporation as of 1 October 2018. Ivaska joins Orion from the University of Turku and will continue working also there with her internationally recognised research team.
F-star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.
Crescendo Biologics Ltd (Crescendo), today announced that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect.
Arix Bioscience, a healthcare and life science company, today announces planned changes to its executive team to prepare for its next phase of growth and development. Dr Joe Anderson, who has served as Chief Executive Officer of Arix since its inception in 2016, will transition to Chief Investment Officer. He will continue to Chair the Investment Committee and as of today, September 4 2018, will step down from the Board of Arix. Executive Chairman of Arix, Jonathan Peacock, will assume corporate and operating responsibilities and, working closely with the Board of Arix, will lead the process of recruiting a Chief Executive Officer.
EuropaBio today confirmed the appointment of Joanna Dupont-Inglis as its new Secretary General.
Commenting on this promotion, EuropaBio chair, Tjerk de Ruiter, said Joanna has an excellent track record of leadership and engagement in this sector. Her experience will be valuable in working together with an increasingly broad community of stakeholders to ensure that the benefits of biotech can be accessed in Europe”.
Roche today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to pursue his career outside of the company effective 30 September 2018. Until a successor is named, Michael Heuer, currently Region Head Europe, Middle East, Africa, and Latin America for Roche Diagnostics will assume the ad interim leadership of Roche’s Diagnostics Division and become a member of the Corporate Executive Committee.
Congenica today announced the appointment of Mrs Wendy Britten as its new Chief Financial Officer (CFO), effective 1st September, 2018. Mrs Britten will have overall control and responsibility for all financial aspects of the business and will play a key role in business development and fundraising activities.
Parexel International Corporation today announced the appointment of Greg Rush as Executive Vice President and Chief Financial Officer.
Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, has announced the appointment of Dr. Namir Hassan as chief scientific officer (CSO).